Drugs / ALN-BCAT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06600321 | Dec 2024 → Sep 2027 expected | hepatocellular carcinoma | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-BCAT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06600321 ↗ |
| Route | Intravenous | “Administered by intravenous (IV) infusion” NCT06600321 ↗ |